Sanofi Pasteur Supports Polio Eradication at First International Stock Exchange Event

LYON, France and SWIFTWATER, Pennsylvania, February 23, 2011
(ots/PRNewswire) -- Sanofi Pasteur, the vaccines division of
sanofi-aventis Group , today will participate in the first
international bell-ringing event by a company listed on NYSE
Euronext. The events will acknowledge past successes and future
challenges in the battle to eradicate polio at the stock exchanges in
New York, Paris, Brussels, Amsterdam and Lisbon.

"Sanofi Pasteur stands shoulder to shoulder with Rotary
International, the World Health Organization, the Bill and Melinda
Gates Foundation and the myriad of other organizations that are
engaged in this critical effort to save lives," said Olivier
Charmeil, President and CEO of Sanofi Pasteur. "Protecting and
improving human health worldwide is the main mission of Sanofi
Pasteur. As a pioneer and leader in the development of polio vaccine
the company stands behind all efforts that will eradicate the
disease."

Sanofi Pasteur has been supporting the Global Polio Eradication
Initiative (GPEI) since its launch in 1988. GPEI's spearheading
partners are Rotary International, the World Health Organization
(WHO), the U.S. Centers for Disease Control and Prevention (CDC), and
UNICEF. Since that time, Sanofi Pasteur has provided more than 5
billion doses of polio vaccine. Between 1997 and 2005, Sanofi Pasteur
donated over 120 million doses for polio eradication to respond to
emergency situations in African countries affected by conflicts. In
response to an outbreak in Egypt and a request from WHO, the company
developed the first monovalent oral polio vaccine, which helped in
declaring Egypt polio free in 2006.

Recently, Sanofi Pasteur responded to a UNICEF request by
committing to provide 400 million doses of polio vaccine in 2011-2012
for use in developing countries. The company has also developed
specially formulated polio vaccines to target specific regions. While
the standard oral polio vaccine (OPV) contains three virus strains,
Sanofi Pasteur also supplies formulations containing one or two
strains for specific situations. In addition to producing multiple
formulations of OPV, the company is a leading supplier of inactivated
polio vaccine (IPV), which is available as a single-disease (polio)
prevention vaccine as well as in various pediatric combination
vaccines to help protect against other diseases.

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company,
discovers, develops and distributes therapeutic solutions to improve
the lives of everyone. Sanofi-aventis is listed in Paris and in New
York . For more information, please visit:
http://www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group,
provides more than 1 billion doses of vaccine each year, making it
possible to immunize more than 500 million people across the globe. A
world leader in the vaccine industry, Sanofi Pasteur offers the
broadest range of vaccines protecting against 20 infectious diseases.
The company's heritage, to create vaccines that protect life, dates
back more than a century. Sanofi Pasteur is the largest company
entirely dedicated to vaccines. Every day, the company invests more
than EUR 1 million in research and development. For more information,
please visit: http://www.sanofipasteur.com or
http://www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995, as amended.
Forward-looking statements are statements that are not historical
facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives,
intentions and expectations with respect to future financial results,
events, operations, services, product development and potential and
statements regarding future performance. Forward-looking statements
are generally identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans" and similar expressions.
Although sanofi-aventis' management believes that the expectations
reflected in such forward-looking statements are reasonable,
investors are cautioned that forward-looking information and
statements are subject to various risks and uncertainties, many of
which are difficult to predict and generally beyond the control of
sanofi-aventis, that could cause actual results and developments to
differ materially from those expressed in, or implied or projected
by, the forward-looking information and statements. These risks and
uncertainties include among other things, the uncertainties inherent
in research and development, future clinical data and analysis,
including post marketing, decisions by regulatory authorities, such
as the FDA or the EMA, regarding whether and when to approve any
drug, device or biological application that may be filed for any such
product candidates as well as their decisions regarding labelling and
other matters that could affect the availability or commercial
potential of such products candidates, the absence of guarantee that
the products candidates if approved will be commercially successful,
the future approval and commercial success of therapeutic
alternatives, the Group's ability to benefit from external growth
opportunities as well as those discussed or identified in the public
filings with the SEC and the AMF made by sanofi-aventis, including
those listed under "Risk Factors" and "Cautionary Statement Regarding
Forward-Looking Statements" in sanofi-aventis' annual report on Form
20-F for the year ended December 31, 2009. Other than as required by
applicable law, sanofi-aventis does not undertake any obligation to
update or revise any forward-looking information or statements.

http://www.sanofipasteur.us

ots Originaltext: sanofi-aventis Group
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contacts: Global Media Relations, Pascal Barollier,
T.+33-(0)4-37-37-50-38, pascal.barollier@sanofipasteur.com; US
MediaRelations, Len Lavenda, T. +1-570-957-0717,
len.lavenda@sanofipasteur.com